In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
REGULATORY UPDATE: FDA Issues Draft Guidance to Support CGT Development
November 19, 2024
AABB Accepting Feedback on Cell and Gene Therapy Standards for Pharmacy
November 19, 2024
FDA Approves Direct-to-Brain Gene Therapy for AADC Deficiency
November 14, 2024